Utility of the Abbott RealTime HCV Genotype Plus RUO Assay Used in Combination with the Abbott RealTime HCV Genotype II Assay
Hepatitis C virus (HCV) can be classified into 7 genotypes (GTs) and 67 subtypes (STs) [1]. In this era of direct-acting antiviral (DAA) therapy for chronic HCV infection, accurate HCV GT determination and ST differentiation (1a versus 1b) remain important factors in the selection of appropriate DAA therapy [2 –5]. The Abbott RealTime HCV Genotype II assay (HCVGT II; Abbott Molecular Inc., Des Plaines, IL), targeting the 5’untranslated (UTR) and nonstructural (NS)5 B regions of the HCV genome, is an HCV genotyping assay approved for in vitro diagnostic use in the U.S. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - January 12, 2018 Category: Virology Authors: Chao He, Jeffrey J. Germer, Elizabeth R. Ptacek, Carl E. Bommersbach, P.Shawn Mitchell, Joseph D.C. Yao Tags: Short communication Source Type: research
Performance of the BioPlex 2200 HIV Ag-Ab assay for identifying acute HIV infection
Screening for HIV infection can be performed with assays that detect HIV antibody (Ab) only (3rd generation assays) or with combination assays that detect HIV antigen (Ag) and Ab [1,2]. The ability to detect HIV Ag in addition to Ab can shorten the window period for detection of HIV infection [3,4]. Assays that provide one test result for Ag and/or Ab are often referred to as 4th generation assays. These assays can detect acute (Ag-positive/Ab-negative) HIV infections [5]. Some Ag/Ab assays provide separate test results for HIV Ag and Ab [3]; these assays have the potential to identify acute infections. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - January 11, 2018 Category: Virology Authors: Susan H. Eshleman, Estelle Piwowar-Manning, Mariya V. Sivay, Barbara Debevec, Stephanie Veater, Laura McKinstry, Linda-Gail Bekker, Sharon Mannheimer, Robert M. Grant, Margaret A. Chesney, Thomas J. Coates, Beryl A. Koblin, Jessica M. Fogel Tags: Short communication Source Type: research
Enterovirus-D68 (EV-D68) in pediatric patients with respiratory infection: The circulation of a new B3 clade in Italy
Human enterovirus D68 (EV-D68) was originally isolated in 1962, and for many years it was considered a rare cause of respiratory disease because it was identified in isolated cases and in small outbreaks [1]. Although outbreaks of EV-D68 infection occurred in the Philippines [2], Italy [3,4], the Netherlands [5] and Japan [6] between 2005 and 2012, it was only in 2014 that the virus gained epidemiological and clinical relevance. In that year, a large-scale outbreak of severe respiratory infections due to this agent, in some cases associated with central nervous system diseases, occurred in the USA and Canada [7], with subs...
Source: Journal of Clinical Virology - January 11, 2018 Category: Virology Authors: Antonio Piralla, Nicola Principi, Luca Ruggiero, Alessia Girello, Federica Giardina, Elisabetta De Sando, Silvia Caimmi, Sonia Bianchini, Gian Luigi Marseglia, Giovanna Lunghi, Fausto Baldanti, Susanna Esposito Source Type: research
Assessing the Risk of CMV Reactivation and Reconstitution of Antiviral Immune Response Post Bone Marrow Transplantation by the QuantiFERON-CMV-Assay and real time PCR
Allogenic hematopoietic stem cell transplantation (alloHSCT) recipients are at significant risk for infectious complications [1,2]. The human cytomegalovirus (CMV) is a life-long persisting virus with a prevalence between 45 and 100% in the general adult population [3]. Recurrent reactivations in healthy individuals are common, but occur usually in the absence of symptoms [4]. In immunocompromised individuals like alloHSCT recipients, CMV reactivation is associated with severe and fatal complications. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - January 9, 2018 Category: Virology Authors: Adalbert Krawczyk, Jessica Ackermann, Birgit Goitowski, Rudolf Trenschel, Markus Ditschkowski, J örg Timm, Hellmut Ottinger, Dietrich W. Beelen, Nico Grüner, Melanie Fiedler Source Type: research
Performance of genotypic algorithms for predicting tropism for HIV-1 CRF01_AE recombinant
The chemokine receptors CCR5 and CXCR4 are the principal co-receptors for entry of HIV-1 into target cells [1,2]. Co-receptor selectivity is determined by genetic sequences within HIV glycoprotein 120 (gp120), particularly in a highly variable and structurally flexible region termed ‘V3′ which is involved in co-receptor binding [3–5]. The CCR5 antagonists, which inhibit HIV-1 binding on the CCR5-coreceptor, are only active on R5-tropic viruses which implies a tropism determination before their prescription. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - January 8, 2018 Category: Virology Authors: C. Soulie, L. Morand-Joubert, J. Cottalorda, C. Charpentier, P. Bellecave, L. Le Guen, S. Yerly, B. Montes, S. Fafi-Kremer, J. Dina, V. Avettand-Fenoel, C. Amiel, C. Roussel, C. Pallier, K. Zafilaza, S. Sayon, A. Signori-Schmuck, A. Mirand, M.A. Trabaud, Tags: Short communication Source Type: research
Renal manifestations of dengue virus infections
Dengue is a significant public health problem in five of six World Health Organization regions [1 –4] and approximately 2.5 billion people live in dengue endemic countries [2]. 100 million cases of dengue fever (DF) and half a million cases of dengue haemorrhagic fever (DHF) are estimated to occur annually. The unique structure of the dengue virus, pathophysiologic responses of the host, the e xistence of different dengue serotypes, and favourable conditions for vector breeding have led to a spread of this infection. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - January 6, 2018 Category: Virology Authors: Padmalal Gurugama, Umesh Jayarajah, Kamani Wanigasuriya, Ananda Wijewickrema, Jennifer Perera, Suranjith L. Seneviratne Source Type: research
Serum HBV DNA plus RNA shows superiority in reflecting the activity of intrahepatic cccDNA in treatment-na ïve HBV-infected individuals
Hepatitis B virus (HBV) infection is a major pathogenic factor leading to chronic hepatitis B (CHB), cirrhosis, liver failure and hepatocellular carcinoma (HCC) [1]. According to the reports of WHO, more than 2 billion people have been infected with HBV and approximately 10% of them finally become chronic HBV infection [2]. Almost 650,000 people die of liver failure, cirrhosis and HCC caused by HBV infection annually [3]. The key step within HBV life cycle is the formation of covalently closed circular DNA (cccDNA), which could serve as the template to produce HBV genome and viral proteins [4 –6]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - January 5, 2018 Category: Virology Authors: Hongxin Huang, Jie Wang, Weijie Li, Ran Chen, Xiangmei Chen, Fengmin Zhang, Dongping Xu, Fengmin Lu Source Type: research
Risk of High-Risk Human Papillomavirus Infection and Cervical Precancerous Lesions with Past or Current Trichomonas Infection: A Pooled Analysis of 25,054 Women in Rural China
Human papillomavirus (HPV) is a sexually transmitted disease (STD) and persistent high-risk HPV (hr-HPV) infection is needed for cervical cancer [1]. Most HPV infections resolve within two years [2], but differences in immune systems and exogenic factors affect hr-HPV clearance and progression to invasive cancer. Concurrent STD infection, such as with chlamydia trachomatis, may affect host immunity, incurring a subsequently increased risk of hr-HPV persistence and progression to high-grade cervical intraepithelial neoplasia (CIN + ) [3–6]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - December 30, 2017 Category: Virology Authors: Rui-Mei Feng, Margaret Z.Wang, Jennifer S. Smith, Li Dong, Feng Chen, Qin-Jing Pan, Xun Zhang, You-Lin Qiao, Fang-Hui Zhao Source Type: research
Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation
Cytomegalovirus (CMV) is still associated with increased morbidity and mortality following transplantation despite effective antiviral treatments [1 –4]. CMV affects allograft survival through “direct effects” such as inflammation enhanced and sustained by the virus, and through “indirect effects” mediated by the immune system [5–9]. Improvements in diagnostic assays such as Polymerase Chain Reaction (PCR) increased sensitivity compa red to the pp65 antigenemia assay for detecting CMV in the blood [10]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - December 29, 2017 Category: Virology Authors: Johan Noble, Philippe Gatault, B énédicte Sautenet, Catherine Gaudy-Graffin, Agnes Beby-Defaux, Antoine Thierry, Marie Essig, Jean-Michel Halimi, Eliza Munteanu, Sophie Alain, Matthias Buchler Source Type: research
Development of a new enzyme immunoassay for improved detection of rotavirus in fecal specimens of vaccinated infants
Group A rotavirus (RVA) is the most common cause of acute viral gastroenteritis in infants and young children and causes approximately 215,000 deaths globally [1,2]. Nearly all children are infected with rotavirus at least once by the age of five years. In the United States, prior to the introduction of rotavirus vaccine, rotavirus gastroenteritis resulted in an estimated 55,000 –70,000 hospitalizations in children less than 5 years of age per year [3,4]. Loss of parental time from work, in caring for ill children, has been estimated millions of dollars per year [5]. (Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - December 26, 2017 Category: Virology Authors: Houping Wang, Merry Liu, Ken Sugata, Yuhuan Wang, Jennifer Hull, Kimberly Foytich, Baoming Jiang Source Type: research
An epidemic surge of influenza A(H3N2) virus at the end of the 2016 –2017 season in Taiwan with an increased viral genetic heterogeneity
Influenza is an annually occurring infectious disease. During seasonal epidemics, typically, 5 –15% of the worldwide population is infected, resulting in 3–5 million cases of severe illness and between 250,000–500,000 deaths every year around the world [1]. Currently, the influenza A(H1N1), A(H3N2) and influenza B viruses are responsible for seasonal epidemics in humans [2,3]. Among the three, the A(H3N2) viruses cause more severe illness and have a higher genetic mutation rate [4]. The A(H3N2) virus also affects the elderly, with increased hospitalization and case fatality rates reported in patients aged 65 years or...
Source: Journal of Clinical Virology - December 22, 2017 Category: Virology Authors: Ji-Rong Yang, Shu-Zhen Hsu, Chuan-Yi Kuo, Hsiang-Yi Huang, Teng-Yung Huang, Hsiao-Chi Wang, Ming-Tsan Liu Source Type: research
An epidemic surge of influenza A(H3N2) virus at the end of the 2016-2017 season in Taiwan with an increased viral genetic heterogeneity
Influenza is an annually occurring infectious disease. During seasonal epidemics, typically, 5-15% of the worldwide population is infected, resulting in 3-5 million cases of severe illness and between 250,000-500,000 deaths every year around the world [1]. Currently, the influenza A(H1N1), A(H3N2) and influenza B viruses are responsible for seasonal epidemics in humans [2,3]. Among the three, the A(H3N2) viruses cause more severe illness and have a higher genetic mutation rate [4]. The A(H3N2) virus also affects the elderly, with increased hospitalization and case fatality rates reported in patients aged 65 years or older ...
Source: Journal of Clinical Virology - December 22, 2017 Category: Virology Authors: Ji-Rong Yang, Shu-Zhen Hsu, Chuan-Yi Kuo, Hsiang-Yi Huang, Teng-Yung Huang, Hsiao-Chi Wang, Ming-Tsan Liu Source Type: research
Editorial Board
(Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - December 21, 2017 Category: Virology Source Type: research
ESCV Membership
(Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - December 21, 2017 Category: Virology Source Type: research
PASCV Membership
(Source: Journal of Clinical Virology)
Source: Journal of Clinical Virology - December 21, 2017 Category: Virology Source Type: research
